Carrie Lynn Kraling from Minneapolis, MN, age 47

Carrie Kraling Phones & Addresses

Minneapolis, MN
Saint Paul, MN
Saint Joseph, MN

Work

Company:

Amerilab technologies
Oct 2011 to Feb 2017
Position:

R and d supervisor

Education

Degree:

Bachelors, Bachelor of Arts
School / High School:

Saint John's University
1995 to 1999
Specialities:

Biochemistry, Chemistry

Skills

Formulation • Gmp • Fda • Technology Transfer • R&D • Quality Assurance • Pharmaceutical Industry • Product Development • Manufacturing • Sop • Project Management • Capa • Nutraceuticals • Project Planning • Quality System • Analytical Chemistry • Chemistry • Validation • Cross Functional Team Leadership • Pharmaceutics • Dea • Process Improvement • Sap • Biotechnology • U.s. Food and Drug Administration • 21 Cfr Part 11 • Business Process Improvement • Formulation Development • Pharmaceuticals • Contract Manufacturing • Fda Gmp • Organic Chemistry • Quality By Design • Software Documentation • Drug Delivery • Research and Development • Standard Operating Procedure • Corrective and Preventive Action • Cgmp • Research Project Management

Industries

Research

Resumes

R And D Manager

view source

Location:

Minneapolis, MN

Industry:

Research

Work:

Amerilab Technologies Oct 2011 - Feb 2017
R and D Supervisor
Amerilab Technologies Oct 2011 - Feb 2017
R and D Manager
Cima Labs Jan 2007 - Sep 2011
Research Associate Vi
Cima Labs Jul 2004 - Jan 2007
Research Associate Iv
Cima Labs Jul 2002 - Jul 2004
Senior Formulator

Education:

Saint John's University 1995 - 1999
Bachelors, Bachelor of Arts, Biochemistry, Chemistry

Skills:

Formulation
Gmp
Fda
Technology Transfer
R&D
Quality Assurance
Pharmaceutical Industry
Product Development
Manufacturing
Sop
Project Management
Capa
Nutraceuticals
Project Planning
Quality System
Analytical Chemistry
Chemistry
Validation
Cross Functional Team Leadership
Pharmaceutics
Dea
Process Improvement
Sap
Biotechnology
U.s. Food and Drug Administration
21 Cfr Part 11
Business Process Improvement
Formulation Development
Pharmaceuticals
Contract Manufacturing
Fda Gmp
Organic Chemistry
Quality By Design
Software Documentation
Drug Delivery
Research and Development
Standard Operating Procedure
Corrective and Preventive Action
Cgmp
Research Project Management

Us Patents

Abuse Resistant Drug Formulation
view source
US Patent:

20130122087, May 16, 2013
Filed:

Dec 31, 2012
Appl. No.:

13/731587
Inventors:

Cima Labs Inc. - Brooklyn Park MN, US
Ehab Hamed - Brooklyn Park MN, US
Derek Moe - Brooklyn Park MN, US
Carrie Kraling - Brooklyn Park MN, US
Lisa Hillman - Brooklyn Park MN, US
Assignee:

CIMA LABS INC. - Brooklyn Park MN
International Classification:

A61K 9/20
US Classification:

424465
Abstract:

A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.

Abuse-Resistant Formulations
view source
US Patent:

20130209560, Aug 15, 2013
Filed:

Feb 23, 2011
Appl. No.:

13/719908
Inventors:

Ehab Hamed - Concord MA, US
Carrie Kraling - Minneapolis MN, US
Assignee:

CIMA LABS Inc. - Brooklyn Park MN
International Classification:

A61K 9/00
A61K 31/485
US Classification:

424470, 514282
Abstract:

This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.

Abuse Resistant Drug Formulation
view source
US Patent:

20110200681, Aug 18, 2011
Filed:

Apr 27, 2011
Appl. No.:

13/095434
Inventors:

Walid Habib - Brooklyn Park MN, US
Ehab Hamed - Brooklyn Park MN, US
Derek Moe - Brooklyn Park MN, US
Carrie Kraling - Brooklyn Park MN, US
Lisa Hillman - Brooklyn Park MN, US
Assignee:

CIMA LABS INC. - Brooklyn Park MN
International Classification:

A61K 9/50
A61K 9/52
A61K 31/485
A61P 25/04
A61P 25/36
US Classification:

424495, 424494, 424496, 424497, 427 221, 514282
Abstract:

A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.

Abuse-Resistant Formulations
view source
US Patent:

20180049974, Feb 22, 2018
Filed:

Nov 2, 2017
Appl. No.:

15/802276
Inventors:

- Brooklyn Park MN, US
Carrie Kraling - Minneapolis MN, US
International Classification:

A61K 9/00
A61K 9/20
A61K 31/485
A61K 9/50
Abstract:

This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.

Carrie Lynn Kraling